$54.37
0.64[1.19%]
At close: Apr 25
$54.37
0[0.00%]
PreMarket: 7:47PM EDT
CRISPR Therapeutics
(NASDAQ:CRSP)Latest News for CRISPR Therapeutics Stock (NASDAQ:CRSP)
CRISPR Therapeutics Stock (NASDAQ: CRSP)
Categories: All
Thursday, April 18, 2024
Wednesday, April 17, 2024
Thursday, April 11, 2024
Thursday, March 21, 2024
Tuesday, March 19, 2024
Tuesday, March 12, 2024
Wednesday, March 06, 2024
Monday, March 04, 2024
Monday, February 26, 2024
Friday, February 23, 2024
Thursday, February 22, 2024
- Smart Money Is Betting Big In CRSP OptionsBenzinga Insights - Feb 22, 2024, 1:15PM
- RBC Capital Maintains Sector Perform on CRISPR Therapeutics, Raises Price Target to $66Benzinga Newsdesk - Feb 22, 2024, 12:40PM
- CRISPR Therapeutics shares are trading higher after Chardan Capital maintained a Buy rating on the stock and raised its price target from $110 to $112.Benzinga Newsdesk - Feb 22, 2024, 11:55AM
- Analog Devices To Rally Around 19%? Here Are 10 Top Analyst Forecasts For ThursdayAvi Kapoor - Feb 22, 2024, 7:23AM
- Chardan Capital Maintains Buy on CRISPR Therapeutics, Raises Price Target to $112Benzinga Newsdesk - Feb 22, 2024, 5:44AM
Wednesday, February 21, 2024
Thursday, February 15, 2024
- What's Going On With Crispr Therapeutics Stock?Erica Kollmann - Feb 15, 2024, 11:36AM
- Reliance Steel & Aluminum Posts Upbeat Earnings, Joins JFrog, AppLovin, Shake Shack And Other Big Stocks Moving Higher On ThursdayAvi Kapoor - Feb 15, 2024, 10:23AM
- Wolfe Research Initiates Coverage On CRISPR Therapeutics with Peer Perform RatingBenzinga Newsdesk - Feb 15, 2024, 6:58AM
Wednesday, February 14, 2024
Tuesday, February 13, 2024
- CRISPR Therapeutics Announces $280M Registered Direct Offering At $71.50/ShareBenzinga Newsdesk - Feb 13, 2024, 8:43AM
- European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY (Exagamglogene Autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)Benzinga Newsdesk - Feb 13, 2024, 2:32AM
Friday, February 09, 2024
Wednesday, January 31, 2024
Monday, January 22, 2024
Thursday, January 18, 2024
Wednesday, January 17, 2024
Tuesday, January 16, 2024
Monday, January 08, 2024
Tuesday, January 02, 2024
Monday, January 01, 2024
Tuesday, December 26, 2023
Friday, December 22, 2023
Wednesday, December 20, 2023
Wednesday, December 13, 2023
- CRISPR Therapeutics Option Alert: Jan 19 $65 Calls Sweep (9) near the Ask: 252 @ $1.75 vs 7372 OI; Ref=$58.46; CRISPR Therapeutics Option Alert: Jan 19 $65 Calls Sweep (6) near the Ask: 181 @ $1.75 vs 7372 OI; Ref=$58.46Charles Gross - Dec 13, 2023, 1:10PM
- Cathie Wood's Ark Invest Sells Nearly $11.5M Worth Of Coinbase Shares As Bitcoin, Crypto Rally Loses SteamBenzinga Neuro - Dec 12, 2023, 11:22PM
Monday, December 11, 2023
- Cathie Wood's Ark Dumps $12.8M Worth Of Grayscale Bitcoin Trust Amid Crypto Rally Losing Wind In SailsBenzinga Neuro - Dec 11, 2023, 10:55PM
- A Closer Look at CRISPR Therapeutics's Options Market DynamicsBenzinga Insights - Dec 11, 2023, 1:16PM
- RBC Capital Maintains Sector Perform on CRISPR Therapeutics, Raises Price Target to $57Benzinga Newsdesk - Dec 11, 2023, 11:40AM
- Truist Securities Maintains Buy on CRISPR Therapeutics, Lowers Price Target to $160Benzinga Newsdesk - Dec 11, 2023, 11:31AM
- CRISPR Therapeutics shares are trading lower after TD Cowen downgraded the stock from Market Perform to Underperform and announced a $30 price target.Benzinga Newsdesk - Dec 11, 2023, 10:54AM
- Barclays Maintains Equal-Weight on CRISPR Therapeutics, Raises Price Target to $61Benzinga Newsdesk - Dec 11, 2023, 8:46AM
- HP To Rally Around 36%? Here Are 10 Top Analyst Forecasts For MondayAvi Kapoor - Dec 11, 2023, 7:45AM
- TD Cowen Downgrades CRISPR Therapeutics to Underperform, Announces $30 Price TargetBenzinga Newsdesk - Dec 11, 2023, 7:24AM
- JMP Securities Maintains Market Outperform on CRISPR Therapeutics, Raises Price Target to $80Benzinga Newsdesk - Dec 11, 2023, 6:29AM
- Needham Maintains Buy on CRISPR Therapeutics, Raises Price Target to $88Benzinga Newsdesk - Dec 11, 2023, 4:30AM